This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
ChuangZhen Chen
Shantou University Medical College Cancer Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-2342-8099
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Prediction of response to chemoradiotherapy is critical for the optimal management of oesophageal cancer, yet it is still an unmet clinical need. This study aims to evaluate the predictive potential of peri-treatment peripheral blood cells (PBC) in disease progression hazard in oesophageal cancer following chemoradiotherapy.
Methods 87 patients with primary oesophageal squamous cell carcinoma were subjected to definitive concurrent chemoradiotherapy in a phase II trial. PBC parameters (haemoglobin, neutrophils, platelets, lymphocytes and monocytes) were collected at 7 time points through the course of radiotherapy. The values of peri-treatment PBC parameters in predicting 3-year cumulative hazard of tumour progression were evaluated.
Results Patients with disease progression displayed distinct distribution patterns of peri-treatment PBC compared to patients without. Greater prediction capabilities for risk of locoregional disease progression were found in PBC collected after the start of radiotherapy compared to their pretreatment counterparts, and in individual parameters rather than cell-to-cell ratios. The most predictive PBC parameters were integrated by summation and designated as a PBC score (PBCS), which further augmented their predictive power. Patients divided according to their PBCS (high vs medium vs low) had significantly different 3-year cumulative hazards of locoregional progression (58% vs 29% vs 7%, P = 0.0017). Multivariate analysis confirmed that PBCS high (HR 12.2, 95%CI 2.0-76.3, P = 0.007) and medium (HR 5.8, 95%CI 1.2-27.7, P = 0.028) are independent indicators of locoregional progression.
Conclusion Peri-treatment PBCS can predict the long-term hazard of locoregional progression after definitive chemoradiotherapy in patients with oesophageal squamous cell carcinoma.
Keywords
Peri-treatment, Peripheral blood cell score, Progression, Oesophageal squamous cell carcinoma, Chemoradiotherapy
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 23 Dec, 2019
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
ChuangZhen Chen
Shantou University Medical College Cancer Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-2342-8099
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 23 Dec, 2019
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Prediction of response to chemoradiotherapy is critical for the optimal management of oesophageal cancer, yet it is still an unmet clinical need. This study aims to evaluate the predictive potential of peri-treatment peripheral blood cells (PBC) in disease progression hazard in oesophageal cancer following chemoradiotherapy.
Methods 87 patients with primary oesophageal squamous cell carcinoma were subjected to definitive concurrent chemoradiotherapy in a phase II trial. PBC parameters (haemoglobin, neutrophils, platelets, lymphocytes and monocytes) were collected at 7 time points through the course of radiotherapy. The values of peri-treatment PBC parameters in predicting 3-year cumulative hazard of tumour progression were evaluated.
Results Patients with disease progression displayed distinct distribution patterns of peri-treatment PBC compared to patients without. Greater prediction capabilities for risk of locoregional disease progression were found in PBC collected after the start of radiotherapy compared to their pretreatment counterparts, and in individual parameters rather than cell-to-cell ratios. The most predictive PBC parameters were integrated by summation and designated as a PBC score (PBCS), which further augmented their predictive power. Patients divided according to their PBCS (high vs medium vs low) had significantly different 3-year cumulative hazards of locoregional progression (58% vs 29% vs 7%, P = 0.0017). Multivariate analysis confirmed that PBCS high (HR 12.2, 95%CI 2.0-76.3, P = 0.007) and medium (HR 5.8, 95%CI 1.2-27.7, P = 0.028) are independent indicators of locoregional progression.
Conclusion Peri-treatment PBCS can predict the long-term hazard of locoregional progression after definitive chemoradiotherapy in patients with oesophageal squamous cell carcinoma.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Loading...